Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions HER2 Expressing Solid Tumors
Phase PHASE1, PHASE2
Enrollment 27
Locations 11 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Genetic: Dose Level 1, VNX-202 — Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
  • Genetic: Dose Level 2, VNX-202 — Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
  • Genetic: Dose Level 3, VNX-202 — Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
  • Genetic: Dose Level 4, VNX-202 — Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion

Primary Outcomes

  • Treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs) (Change from Baseline to Year 5 post dosing)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-11-18
Completion: 2033-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 27 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vironexis Biotherapeutics Inc.
Contact Information
Study Contact:
Allen Reha
908-938-6019
allen.reha@vironexis.com
Myo Zaw
424-535-1874
clinicaltrials@vctcare.com
Valkyrie Clinical Trials
Julia Etchart
805-701-0185
julia.etchart@sarahcannon.com
SCRI Denver DDU at HealthOne
Interventions
  • Genetic: Dose Level 1, VNX-202 — Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
  • Genetic: Dose Level 2, VNX-202 — Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
  • Genetic: Dose Level 3, VNX-202 — Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
  • Genetic: Dose Level 4, VNX-202 — Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
Study Locations (11 sites)
Valkyrie Clinical Trials, Los Angeles, California 90067 United States
SCRI Denver DDU at HealthOne, Denver, Colorado 80218 United States
Mayo Clinic, Jacksonville, Florida 32224 United States
Mayo Clinic, Rochester, Minnesota 55095 United States
Hackensack Medical Center, Hackensack, New Jersey 07601 United States
Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States
Cleveland Clinic, Cleveland, Ohio 44195 United States
Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania 19107 United States
SCRI Oncology Partners, Nashville, Tennessee 37203 United States
UT MD Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * Age: ≥18 years of age * Histologically or cytologically confirmed diagnosis of HER-2 positive solid tumor as defined in the protocol * Part 1: presence of advanced or metastatic disease that has progressed during or following previous treatment * Part 2: Early stage HER-2 positive cancers with high risk for relapse following completion of SOC or after neoadjuvant systemic treatment * AAV specified capsid total antibody ≤1:400 * ECOG performance status of 0 or 1 * Life expectancy ≥3 months * Protocol-specified ranges for renal, liver, cardiac and pulmonary function * Protocol-specified ranges for hematology parameters Exclusion Criteria: * Hepatoxicity (AST or ALT \> 2x upper limit of normal) * Known active CNS or leptomeningeal disease * History of thrombotic microangiopathy or cardiomyopathy, or evidence of sensory neuropathy * Pregnant or nursing (lactating) women * History of other malignancy within 5 years prior to screening as defined in protocol * History of hypersensitivity to corticosteroids or history of corticosteroid-related toxicity Concurrent anti-cancer treatment in another investigational trial
Conditions Breast Cancer Female
Phase NA
Enrollment 63
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Patients with localized breast cancer undergo treatment that includes breast surgery, which always alters their body image, complemented by optional additional treatments depending on the specifics and severity of their disease. These treatments are multimodal and may include chemotherapy, radiotherapy, targeted anticancer treatments, and hormone therapy, followed by prolonged monitoring for at least 5 years. A recent study showed that the announcement of cancer and its treatments is a source of reactive anxiety for 47% of patients at the time of diagnosis, which can be associated with depression in 59% of cases before chemotherapy. Anxiety increases with the intensity of treatments and is higher when chemotherapy is administered, especially in younger patients (under 50 years old). The integrative multidisciplinary care available in treatment centers (psychologist, adapted physical activity, socio-aesthetician), combined with external support through associative networks (art therapy, music therapy, etc.), is crucial for improving quality of life and treatment side effects. Sophrology is one of these complementary therapies recommended by Association Francophone Des Soins Oncologiques De Support (French Association for Supportive Care in Oncology) within or outside the healthcare structure and is validated as supportive care. Its principle is to positively enhance patients' qualities and resources by altering states of consciousness, allowing individuals to find a balance between their thoughts, emotions, and behaviors. The three fundamental principles are to bring the body schema to a more lived reality, reinforce positive action, and develop objective reality. The "mindfulness" techniques used in sophrology include dynamic relaxation and sophronizations. Sophrology is based on the scientific principles of mindfulness meditation (developing attentional resources and body awareness by modulating brain waves). Studies have shown the benefits of mindfulness in managing stress, certain psychosomatic conditions, and chronic pain. Improvements in overall quality of life, stress symptoms, and sleep quality have been reported in the evaluation of a mindfulness meditation program for cancer patients. A trial demonstrated the beneficial effect of group mindfulness meditation on the anxiety of women who had undergone chemotherapy for breast cancer. Today, although sophrology is regularly used in medical care, no robust scientific study has evaluated its benefit in oncology. Institut National de la Santé et de la Recherche Médicale, together with Haute Autorité de la Santé, highlighted in its 2020 report on sophrology the significant need to scientifically assess the interest of sophrology in medical care. However, the use and accessibility of complementary therapies, including sophrology, are very unequal across France and depend on hospitals, geography, patient mobility, and sometimes the financial ability of patients to access paid complementary…

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: sophrology sessions — Two sophrology sessions will be conducted in the experimental group. The first session (S1) should take place on Cycle 1 Day 1 or within a maximum of 3 weeks following Cycle 1 Day 1. The second session (S2) should be conducted within 3 to 4 weeks after the first session.
  • Device: Morphee Device — Patients will be encouraged to perform at least one daily ambulatory sophrology session with the Morphée® device, according to a support plan defined with the sophrologist.

Primary Outcomes

  • To measure the evolution of anxiety in patients undergoing adjuvant or neoadjuvant chemotherapy treatment, depending on whether they benefit from a sophrology program through an ambulatory sophrology device (Morphée®) (Inclusion and 3 months after start of treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-15
Completion: 2027-08-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 63 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut Cancerologie de l'Ouest
Principal Investigators:
  • Simmet (PRINCIPAL_INVESTIGATOR) - Institut de Cancérologie de l'Ouest
Contact Information
Study Contact:
Victor Simmet, MD
+33 2 41 35 27 00
victor.simmet@ico.unicancer.fr
Lucie Labarre
lucie.labarre@ico.unicancer.fr
Simmet
+33 2 41 35 27 00
victor.simmet@ico.unicancer.fr
Institut de Cancérologie de l'Ouest - site Angers
Interventions
  • Behavioral: sophrology sessions — Two sophrology sessions will be conducted in the experimental group. The first session (S1) should take place on Cycle 1 Day 1 or within a maximum of 3 weeks following Cycle 1 Day 1. The second session (S2) should be conducted within 3 to 4 weeks after the first session.
  • Device: Morphee Device — Patients will be encouraged to perform at least one daily ambulatory sophrology session with the Morphée® device, according to a support plan defined with the sophrologist.
Study Locations (3 sites)
Institut de Cancérologie de l'Ouest - site Angers, Angers, 49055 France
CH Cholet, Cholet, 49300 France
Institut de Cancérologie de l'Ouest - site Saint Herblain, Saint-Herblain, 44805 France
Eligibility Criteria
Inclusion Criteria: 1. Patient with localized breast cancer 2. Patient \> 18 years old 3. Patient requiring chemotherapy +/- combined with immunotherapy or targeted therapy, in neoadjuvant or adjuvant seeting defined by the multidisciplinary consultation meeting. 4. Patient with signed consent 5. Patient has national health insurance coverage Exclusion Criteria: 1. Patient previously treated with chemotherapy for breast cancer 2. Patient with metastatic breast cancer 3. History of psychiatric illness or treatment with neuroleptics, antidepressants or thymoregulators thymoregulator, prior to discovery of cancer (except resolved depressive episode, without psychiatric treatment for at least 2 years). An anxiolytic or hypnotic treatment prescribed after diagnosis is authorized 4. Patient suffering from psychiatric disorders, delusional phases, schizophrenia contraindicating practice of sophrology 5. Patient who has already had an introduction to sophrology in the context of her pathology, or who plans to start sophrology within within 3 months of the start of treatment outside the hospital structure and by her own means 6. Patient does not understand or speak French 7. Cognitive impairment or inability to understand, compromising participation in the study and use and understanding of the device 8. Patient under legal protection, guardianship or trusteeship 9. Inability to undergo protocol monitoring for geographical or social reasons. 10. Patient participating in another interventional study evaluating supportive care
Conditions Breast Cancer
Phase PHASE1, PHASE2
Enrollment 74
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Patients with breast cancer are commonly treated with taxane chemotherapy. Some very common side effects of taxanes, such as anemia and peripheral neuropathy, are often as not well addressed during treatment, resulting in dose reductions, dose delays and early discontinuation (collectively called relative dose intensity) of these chemotherapy agents in 15-80 % of patients on these drugs. This reduction in relative dose intensity (RDI) results in worse clinical outcomes such as progression free and overall survival. Pre-clinical studies in mouse models subjected to standardized chemotherapy regimens containing paclitaxel or oxaliplatin have shown that the nutritional supplement Epidiferphane reduces both neuropathy and anemia. This study will investigate whether the use of Epidiferphane in patients with breast cancer receiving taxane chemotherapy results in an attenuation of the side effects experienced, as well as an improvement in tumor response rate. The safety and maximum tolerated dose of Epidiferphane in this patient population will also be determined in this study.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Epidiferphane — During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each taxane regimen (docetaxel or paclitaxel). All subjects in the phase II portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen. Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months.
  • Drug: Taxane Chemotherapy — All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly, nab-paclitaxel given weekly or every 3 weeks or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.

Primary Outcomes

  • Cmax of Epidiferphane's components (24 hours)
  • Cmax of taxanes (24 hours)
  • Concentration at 24 hours (C24 hours) of Epidiferphane's components (24 hours)
  • Concentration at 24 hours (C24 hours) of taxanes (24 hours)
  • Maximum tolerated dose of Epidiferphane in patients with breast cancer who are being treated with taxanes (4 months)
  • Rate of Common Terminology Criteria for Adverse Events (CTCAE) v5.0 grade 2 or higher neuropathy (4 months)
  • Rate of Common Terminology Criteria for Adverse Events (CTCAE) v5.0 grade 1 or higher anemia (4 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2023-03-30
Completion: 2026-12
Eligibility
Age: 18 Years – 99 Years
Sex: ALL
Volunteers: false
Enrollment: 74 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Florida
Principal Investigators:
  • Coy Heldermon (PRINCIPAL_INVESTIGATOR) - University of Florida
Contact Information
Study Contact:
Priya Gurjar
352-273-6772
PMO@cancer.ufl.edu
Danielle Ogden
352-733-0488
d.ogden@ufl.edu
University of Florida
Coy Heldermon, MD, PhD
University of Florida
Interventions
  • Drug: Epidiferphane — During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each taxane regimen (docetaxel or paclitaxel). All subjects in the phase II portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen. Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months.
  • Drug: Taxane Chemotherapy — All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly, nab-paclitaxel given weekly or every 3 weeks or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
Study Locations (1 sites)
University of Florida, Gainesville, Florida 32608 United States
Eligibility Criteria
Inclusion Criteria: * Must be at least 18 years of age * Subjects on the phase I portion must either be initiating neoadjuvant chemotherapy or have a clinical diagnosis of metastatic breast cancer. Subjects on the phase II portion must have a clinical diagnosis of breast cancer of any stage and histology. * Must be about to start a new treatment regimen containing either paclitaxel given weekly or docetaxel given every 3 weeks or nab-paclitaxel given weekly or every 3 weeks at UF Health, at one of the following doses: * Paclitaxel weekly at 80-90 mg/m2 * Nab-paclitaxel weekly at 75-125 mg/m2 or every three weekly at 260 mg/m2 * Docetaxel every three weeks at 75-100 mg/m2 * An ECOG Performance Status less than or equal to 3 based on treating physician assessment * Must continue cancer therapy at UF Health for at least the next three months * Must not have more than one active malignancy at the time of enrollment (Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen \[as determined by the treating physician and approved by the PI\] may be included. * A functioning digestive tract with no obstruction * Subjects must be willing to avoid regular consumption of green tea and curcumin supplements for the duration of trial participation. * Written informed consent obtained from the subject and the ability for the subject to comply with all the study-related procedures. * Subjects of childbearing potential (SOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study. * Subjects with partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study. Exclusion Criteria: * Must not be receiving any other investigational agents * Subjects of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and following completion of taxane therapy for an additional 6 months for subjects of child bearing potential and 3 months for subjects with partners of child bearing potential. * Subjects who are pregnant or breastfeeding * Active systemic infection considered to be opportunistic, life threatening or clinically significant at the time of treatment. * Psychiatric illness or social situation that would limit compliance with trial requirements. * Known allergy to turmeric, broccoli, or green tea. * Subjects must not be on treatment with strong CYP3A4 inhibitors such as tacrolimus or on verapamil during the trial. * History of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding (e.g. hemoglobin \< 10 mg/dL, CTCAE v 5.0 grade 3 or higher neutropenia or thrombocytopenia) giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician. * Prisoners or subjects who are involuntarily incarcerated. * Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness. * Subjects demonstrating an inability to comply with the study and/or follow-up procedures. * CTCAE v 5.0 grade 2 or higher peripheral sensory or motor neuropathy * CTCAE v 5.0 grade 1 or higher paresthesia * Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) \>2.5 × the upper limit of normal (ULN) * Total bilirubin (TBL) \>1.5 × ULN or \>3 × ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) * Glomerular filtration rate (GFR) \<50 mL/min * Red blood cell infusions \< 30 days prior to treatment
Conditions ER-Positive Breast Cancer, HER2-negative...
Phase PHASE2
Enrollment 28
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The study will investigate if CDK4/6 inhibitor holiday will reset the cell cycle process to respond to the combination of fulvestrant and abemaciclib, and this approach may represent an effective therapeutic strategy to manage such patients.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Fulvestrant Run-In — The study is evaluating if a drug holiday (post CDK inhibitors progression) will reset the cell cycle machinery to be responsive to Abemaciclib and Fulvestrant.

Primary Outcomes

  • Time to treatment failure (TTF) for fulvestrant plus abemaciclib with a 1-month run-in of fulvestrant (TTF will be defined as time from start of therapy to discontinuation for any cause.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-02-25
Completion: 2027-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 28 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Methodist Hospital Research Institute
Collaborators: Eli Lilly and Company
Principal Investigators:
  • Polly Niravath, MD (PRINCIPAL_INVESTIGATOR) - The Methodist Hospital Research Institute
Contact Information
Study Contact:
Polly Niravath, MD
713-441-0629
ccresearch@houstonmethodist.org
Polly Niravath, MD
713-441-0629
ccresearch@houstonmethodist.org
Houston Methodist Cancer Center
Interventions
  • Drug: Fulvestrant Run-In — The study is evaluating if a drug holiday (post CDK inhibitors progression) will reset the cell cycle machinery to be responsive to Abemaciclib and Fulvestrant.
Study Locations (1 sites)
Houston Methodist Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: 1. Male or Female \>18 years of age on the day of informed consent signing. 2. Progression on a CDK4/6 inhibitor in combination with an AI immediately prior to the enrollment on this study 3. Histologically confirmed ER-positive, HER2-negative metastatic breast cancer. ER-positive is defined as ≥1% immunohistochemical (IHC) staining of any intensity. HER2 test result is negative if a single test (or both tests) performed show: * IHC 1+ or 0 * In situ hybridization negative based on: * Single-probe average HER2 copy number \<4.0 signals/cell * Dual-probe HER2/CEP17 ratio \<2.0 with an average HER2 copy number \<4.0 signals/cell. 4. Measurable disease according to the RECIST 1.1 or bone-only disease. 5. Postmenopausal status or receiving ovarian ablation with a gonadotropin-releasing hormone (GnRH) agonist. Postmenopausal status is defined by any one of the following criteria: * Prior bilateral oophorectomy * Age ≥55 years * Age \<55 years and amenorrheic for at least 12 months (spontaneous cessation of menses for 12 consecutive months or more in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression) and follicle-stimulating hormone and estradiol levels in the postmenopausal range without an alternative cause If the patient does not meet criteria for postmenopausal status but is receiving ovarian ablation therapy with a GnRH agonist, the patient is eligible for this trial, provided that the GnRH agonist is started at least 2 weeks prior to the first dose of trial treatment. 6. Eastern Cooperative Oncology Group performance status of 0 or 1. 7. Life expectancy ≥6 months. 8. Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events \[CTCAE\] Grade ≤1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to randomization. A washout period of at least 21 days is required between last chemotherapy dose and randomization (provided the patient did not receive radiotherapy). Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 21 days is required between end of radiotherapy and randomization. 9. Adequate organ function: * Absolute neutrophil count ≥1500/µL (without granulocyte colony stimulating factor support within 2 weeks of laboratory test used to determine eligibility) * Platelets ≥100,000/µL (without transfusion within 2 weeks of laboratory test used to determine eligibility) * Hemoglobin ≥9 g/dL (without blood transfusion) * White blood cell count \>2,500/µL and \<15,000/µL * Lymphocyte count ≥500/µL * Serum bilirubin ≤1.5x upper limit of normal (ULN; patients with known Gilbert's disease who have serum bilirubin level ≤3 x ULN may be enrolled) * Serum transaminases (aspartate transaminase \[AST\] or alanine transaminase \[ALT\]) activity ≤3.0 x ULN with normal alkaline phosphatase (\[ALP\]; patients with liver metastases ≤5 x ULN) OR AST and ALT ≤1.5 x ULN with ALP \>2.5 x ULN * International normalized ratio and activated partial thromboplastin time ≤1.5 x ULN * Serum creatinine at or below the institutional normal value. 10. Able to swallow oral medication. 11. Patients who are made postmenopausal through use of GNRH agonists must be willing to use an adequate method of contraception for the course of the trial through 1 year after the last dose of trial treatment. 12. Patients who are made postmenopausal through use of GNRH agonists should have a negative serum pregnancy (β-human chorionic gonadotropin) within 7 days prior to trial treatment administration. 13. Willing and able to provide written informed consent/assent for the trial. Exclusion Criteria: 1. Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 3 weeks of trial treatment administration. 2. Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to trial treatment administration or who has not recovered (i.e., ≤ Grade 1 or at baseline) from AEs due to a previously administered agent. Note: If the patient received major surgery, she must have recovered adequately from the toxicity and/or complications from the intervention prior to starting the trial treatment. 3. The patient has had major surgery within 14 days prior to starting the study. 4. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. 5. The patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment \[e.g. estimated creatinine clearance \<30ml/min\], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea). 6. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator. 7. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 8. Concurrent use of strong cytochrome P450 (CYP)3A inhibitors or inducers. 9. Hypersensitivity to fulvestrant, abemaciclib, or any of their excipients. 10. Manifestations of malabsorption due to prior gastrointestinal surgery, gastrointestinal surgery disease, or an unknown reason. 11. Has a bleeding disorder or currently taking anticoagulants. 12. Has active hepatitis B (detectable hepatitis B surface antigen) or active hepatitis C infection (detectable hepatitis C RNA). 13. Has active systemic bacterial infection (requiring intravenous \[IV\] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C \[for example, hepatitis B surface antigen positive\]. Screening is not required for enrollment. 14. Has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. 15. Documented brain metastases that are untreated, symptomatic, or require therapy to control symptoms. Patients with previously diagnosed brain metastases are eligible if they have completed treatment at least one month prior to trial treatment administration, are neurologically stable, and have recovered from effects of radiotherapy or surgery. * Any corticosteroid use for brain metastases must have been discontinued without the subsequent appearance of symptoms for ≥2 weeks before trial treatment administration. * Treatment for brain metastases may have included whole brain radiotherapy, radiosurgery, or a combination as was deemed appropriate by the treating physician. * Patients who meet the above criteria and are clinically stable on anticonvulsant medication are eligible only if their anticonvulsant does not alter hepatic CYP activity in a way that might interfere with the metabolism of abemaciclib. 16. Have received any live vaccination within 28 days of trial treatment administration. 17. History within the last 12 months of any of the following conditions: syncope of cardiovascular
Conditions Breast Cancer, Prostate Cancer, Colorect...
Phase NA
Enrollment 51
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Researchers think that exercise may be able to prevent cancer from coming back by lowering ctDNA levels. The purpose of this study is to explore how aerobic exercise (exercise that stimulates and strengthens the heart and lungs and improves the body's use of oxygen) can reduce the level of ctDNA found in the blood. During the study, the highest level of exercise that is practical, is safe, and has positive effects on the body that may prevent the return of cancer (including a decrease in ctDNA levels) will be found. Each level of exercise tested will be a certain number of minutes each week. Once the best level of exercise is found, it will be tested further in a new group of participants. All participants in this study will have been previously treated for breast, prostate, or colorectal cancer.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Sequential Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Other: Exercise — Exercise therapy in both phases will consist of individualized walking delivered 3 to 6 times weekly (over a 7-day period). Exercise treatment will be delivered for up to 18 months, or until progression of disease or withdrawal of consent, whichever comes first. The phase 1a trial will assess five doses of exercise therapy (i.e., 90, 150, 225, 300, and 375 mins/wk) delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule. The phase 1b trial will only test one dose of exercise therapy - the RP2D identified in the phase 1a trial.

Primary Outcomes

  • Identify the recommended phase 2 dose (RP2D) of exercise for testing in the phase 1b. (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-10-30
Completion: 2028-02-13
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 51 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Lee Jones, MD (PRINCIPAL_INVESTIGATOR) - City of Hope Medical Center
Contact Information
Study Contact:
Lee Jones, MD
6262184673
leejones@coh.org
Lee Jones, MD
6262184673
leejones@coh.org
City of Hope Medical Center
Lee Jones, MD
City of Hope Medical Center
Interventions
  • Other: Exercise — Exercise therapy in both phases will consist of individualized walking delivered 3 to 6 times weekly (over a 7-day period). Exercise treatment will be delivered for up to 18 months, or until progression of disease or withdrawal of consent, whichever comes first. The phase 1a trial will assess five doses of exercise therapy (i.e., 90, 150, 225, 300, and 375 mins/wk) delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule. The phase 1b trial will only test one dose of exercise therapy - the RP2D identified in the phase 1a trial.
Study Locations (9 sites)
City of Hope Medical Center, Durate, California 91010 United States
Natera, Inc. (Data or Specimen Analysis Only), San Carlos, California 94070 United States
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey 07920 United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey 07748 United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey 07645 United States
Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York 11725 United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York 10604 United States
Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York 11553 United States
Eligibility Criteria
Inclusion Criteria: * Postsurgical diagnosis of patients with primary solid tumors at high-risk of relapse as defined by one of the following: ° High-risk primary solid tumor (e.g., colorectal, ovarian, non-small cell lung cancer) (colorectal cancer only for Phase 1a) * Stage 3 or * ctDNA positive ° High-risk breast cancer * Residual invasive disease in the breast or the lymph nodes following completion of neoadjuvant chemotherapy (NACT), * Estrogen receptor (ER), and/or progesterone receptor (PR) positive and HER2 negative, * CPS-EG score ≥ 3, * CPS-EG score ≥2 w ith ypN+, or * Recurrence score ≥ 25 * No evidence of disease * Age ≥ 18 * Interval of ≥ 1 month but ≤ 2 years following completion of all definitive adjuvant therapy * Non-exercising (i.e., \< 30 minutes of moderate and \< 20 mins of vigorous exercise/wk), as assessed by remote activity and heart rate tracking for a 7-day period prior to study entry) ° If ≥ 30 minutes but less than 45 minutes of moderate exercise/week, or if ≥ 20 minutes but less than 30 minutes of vigorous exercise/week, patients may be eligible, at the discretion of the PI. * Cleared for exercise participation as per screening clearance via PAR-Q+ * Willingness to comply with all study-related procedures Exclusion Criteria: * Enrollment onto any other interventional investigational study except interventions determined by the PI not to confound study outcomes * Any other current diagnosis of invasive cancer of any kind * Distant metastatic malignancy of any kind * Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation
Conditions Breast Cancer
Phase PHASE3
Enrollment 420
Locations 210 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative, PIK3CA-mutated, locally advanced (LA) or metastatic breast cancer (mBC), who progressed during or after cyclin dependent kinase 4/6i (CDK4/6i)-based therapy. Enrollment for the main study is now complete.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Inavolisib — Participants will be administered a 9 milligram (mg) inavolisib tablet orally once a day (PO QD) on Days 1-28 of each 28-day cycle of main study and sub-study.
  • Drug: Fulvestrant — Participants will be administered 500 mg of fulvestrant on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle of main study and sub-study.
  • Drug: Alpelisib — Alpelisib will be administered to participants at the approved dose in combination with fulvestrant: 300 mg taken PO QD and on days 1-28 of each 28-day cycle.
  • Drug: Bupropion — Participants will be administered bupropion PO on Day -3 and Day 12 of Cycle 1 of the sub-study.
  • Drug: Omeprazole — Participants will be administered omerprazole PO on Day -4 and Day 11 of Cycle 1 of sub-study.
  • Drug: Midazolam — Participants will be administered midazolam PO on Day -4 and Day 11 of Cycle 1 of sub-study.

Primary Outcomes

  • Blinded Independent Central Review (BICR)-Assessed Progression Free Survival (PFS) (From randomization until disease progression or death due to any cause (up to approximately 64 months))
  • Sub-study: Maximum observed Drug Concentration (Cmax) for Midazolam (Day -4 and -3 of Cycle (C) 1, Day (D) 11 and C1D12. A cycle is 28 days.)
  • Sub-study: Cmax for Bupropion (Day -3, -2, -1 of C1D1, C1D12, C1D13, C1D14 and C1D15. A cycle is 28 days.)
  • Sub-study: Cmax for Omeprazole (Day -4 and -3 of C1D11 and C1D12. A cycle is 28 days.)
  • Sub-study: Area Under the Concentration-Time Curve From Time 0 to Last Measurable Concentration (AUC [0-last]) for Midazolam (Day -4 and -3 of C1D11 and C1D12. A cycle is 28 days.)
  • Sub-study: AUC (0-last) for Bupropion (Day -3, -2, -1 of C1D1, C1D12, C1D13, C1D14 and C1D15. A cycle is 28 days.)
  • Sub-study: AUC (0-last) for Omeprazole (Day -4 and -3 of C1D11 and C1D12. A cycle is 28 days.)
  • Sub-study: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC [0-infinity]) for Midazolam (Day -4 and -3 of C1D11 and C1D12. A cycle is 28 days.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-06-07
Completion: 2029-03-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 420 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hoffmann-La Roche
Principal Investigators:
  • Clinical Trials (STUDY_DIRECTOR) - Hoffmann-La Roche
Contact Information
Study Contact:
Reference Study ID Number: WO43919 https://forpatients.roche.com/ No attachments to email below
888-662-6728 (U.S. and Canada)
global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Interventions
  • Drug: Inavolisib — Participants will be administered a 9 milligram (mg) inavolisib tablet orally once a day (PO QD) on Days 1-28 of each 28-day cycle of main study and sub-study.
  • Drug: Fulvestrant — Participants will be administered 500 mg of fulvestrant on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle of main study and sub-study.
  • Drug: Alpelisib — Alpelisib will be administered to participants at the approved dose in combination with fulvestrant: 300 mg taken PO QD and on days 1-28 of each 28-day cycle.
  • Drug: Bupropion — Participants will be administered bupropion PO on Day -3 and Day 12 of Cycle 1 of the sub-study.
  • Drug: Omeprazole — Participants will be administered omerprazole PO on Day -4 and Day 11 of Cycle 1 of sub-study.
Study Locations (210 sites)
Marin Cancer Care Inc, Greenbrae, California 94904 United States
Cancer Blood and Specialty Clinic, Los Alamitos, California 90720 United States
Los Angeles Cancer Network, Los Angeles, California 90017-4803 United States
University of California, Irvine Medical Center, Orange, California 92868 United States
UC Davis Comprehensive Cancer Center, Sacramento, California 95817 United States
Rocky Mountain Cancer Centers, Denver, Colorado 80220 United States
Banner MD Anderson Cancer Center, Greeley, Colorado 85234 United States
Eastern CT Hematology and Oncology Associates, Norwich, Connecticut 06360-2740 United States
Cancer Care Centers of Brevard, Palm Bay, Florida 32901 United States
Cleveland Clinic Florida, Weston, Florida 33331 United States
Eligibility Criteria
Inclusion Criteria for Main Study and Sub-study: * If pre/perimenopausal women and men treatment with luteinizing hormone-releasing hormone (LHRH) agonist therapy beginning at least 2 weeks prior to Day 1 of Cycle 1 * Histologically or cytologically confirmed adenocarcinoma of the breast that is locally advanced or metastatic and is not amenable to surgical or radiation therapy with curative intent * Documented HR +/ HER2- tumor according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines * Confirmation of biomarker eligibility: detection of specified mutation(s) of PIK3CA via specified test * Disease progression after or during treatment with a combination of CDK4/6i and endocrine therapy: \<= 2 prior lines of systemic therapy in mBC setting; CDK4/6i based therapy does not need to be the last one received prior study entry; one line of chemotherapy in mBC setting allowed * Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) * Participants for whom endocrine-based therapy is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study, as per national or local treatment guidelines * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 * Life expectancy of \> 6 months * Adequate hematologic and organ function prior to initiation of study treatment Exclusion Criteria for both Main Study and Sub-study: * Metaplastic breast cancer * Prior treatment in locally advanced or metastatic setting with any PI3K, AKT, or mTOR inhibitor or any agent whose mechanism of action is to inhibit the PI3K/-AKT/-mTOR pathway * Participant who relapsed with documented evidence of progression \> 12 months from completion of adjuvant CDK4/6i based therapy with no treatment for metastatic disease * Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes * Inability or unwillingness to swallow pills * Malabsorption syndrome or other condition that would interfere with enteral absorption * Any history of leptomeningeal disease or carcinomatous meningitis * Known and untreated, or active central nervous system (CNS) metastases. Participants with a history of treated CNS metastases are eligible if they meet specific certain criteria * Any concurrent ocular or intraocular condition that, in the opinion of the investigator, would require medical or surgical intervention during the study period to prevent or treat vision loss that might result from that condition * Active inflammatory or infectious conditions in either eye or history of idiopathic or autoimmune-associated uveitis in either eye * Requirement for daily supplemental oxygen * Symptomatic active lung disease, including pneumonitis * History of or active inflammatory bowel disease * Any active bowel inflammation * Clinically significant and active liver disease, including severe liver impairment, viral or other hepatitis, current alcohol abuse, or cirrhosis * Participants with known human immunodeficiency virus infection that meet specific criteria * History of other malignancy within 5 years prior to screening, except for cancers with very low risk of recurrence * Chronic therapy of \>= 10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids or immunosuppressants for a chronic disease * Active ongoing osteonecrosis of the jaw Exclusion Criteria for Main Study Only: * Pregnant, lactating, or breastfeeding, or intending to become pregnant during the study or at least 60 days after the final dose of study treatment * Known active, systemic infection at study enrollment, or any major episode of infection requiring treatment with intravenous antibiotics or hospitalization within 7 days prior to Day 1 of Cycle 1 * Investigational drug(s) within 4 weeks before randomization or within 5 half-lives of the investigational drug(s), whichever is longer * Allergy or hypersensitivity to components or excipients of the inavolisib, fulvestrant, or alpelisib formulations * History of severe cutaneous reactions like Stevens-Johnson Syndrome, Erythema Multiforme, Toxic Epidermal Necrolysis, or Drug Reaction with Eosinphilia and Systemic Symptoms Exclusion Criteria for Sub-study Only: * Pregnant, lactating, or breastfeeding, or intending to become pregnant during the substudy or within 2 weeks after the final dose of inavolisib and within 2 years after the final dose of fulvestrant, whichever is longer * Known active, systemic infection at study enrollment, or any major episode of infection requiring treatment with intravenous antibiotics or hospitalization within 7 days prior to Day -4 of Cycle 1 * Investigational drug(s) within 4 weeks prior to Day -4 or within 5 half-lives of the investigational drug(s), whichever is longer * Allergy or hypersensitivity to components or excipients of the inavolisib, fulvestrant formulations * Treatment with mild, moderate, or strong inducers of CYP2B6, CYP3A4, and/or CYP2C19 (including St. John's Wort) within 14 days or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study treatment on Day -4 until after the final PK sample has been collected on Day 15 of Cycle 1 * Treatment with mild, moderate, or strong inhibitors of CYP2B6, CYP3A4, and/or CYP2C19 (including grapefruit juice or supplements) within 14 days or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study treatment on Day -4 until after the final PK sample has been collected on Day 15 of Cycle 1
Conditions Breast Cancer
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

A breast reconstruction after mastectomy, either due to breast cancer or a high lifetime risk for cancer, is performed to increase the patient's quality of life. However, there are studies that show that some women regret their decision to have breast reconstruction. There are also studies demonstrating similarities in the general patterns of psychosocial adjustment and quality of life among women with breast cancer who have undergone breast-conserving surgery, mastectomy alone, and mastectomy combined with breast reconstruction. Hence, it is unclear which women actually benefit from a breast reconstruction. The concept of quality of life is connected to patient satisfaction and body image/investment. Therefore, the aim of this project is to examine the effects of patient expectations and body image on the patient reported outcomes of breast reconstruction, to improve preoperative information and postoperative care for women considering a breast reconstruction.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Implant-based breast reconstruction — All types of implant based breast reconstructions
  • Procedure: Autologous breast reconstruction — All types of autologous breast reconstructions
  • Procedure: Combined methods — All types of breast reconstructions combining autologous and implant based techniques

Primary Outcomes

  • Patient satisfaction with breast reconstruction measured with Breast Q reconstruction (2 years)
  • Patient expectations measured with Breast Q expectations (2 years)
  • Body image measured with Multidimensional body-self relations questionnaire- appearance scales (MBSRQ-AS) (2 years)
  • Body image investment measured with Appearance schemas inventory-revised (ASI-R) (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-02-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vastra Gotaland Region
Principal Investigators:
  • Emma Hansson, PhD (PRINCIPAL_INVESTIGATOR) - Göteborg University
Contact Information
Study Contact:
Emma Hansson, PhD
+46313421000
emma.em.hansson@vgregion.se
Linn Weick, MA
+46 31 342 10 00
linn.weick@vgregion.se
Sahlgrenska university hospital
Interventions
  • Procedure: Implant-based breast reconstruction — All types of implant based breast reconstructions
  • Procedure: Autologous breast reconstruction — All types of autologous breast reconstructions
  • Procedure: Combined methods — All types of breast reconstructions combining autologous and implant based techniques
Study Locations (1 sites)
Sahlgrenska university hospital, Gothenburg, 413 45 Sweden
Eligibility Criteria
Inclusion Criteria: * Biological women with breast cancer or high risk for breast cancer who want post-mastectomy breast reconstruction * Age \> 18 years Exclusion Criteria: * Inability to give informed consent * Inability to understand Swedish * Relaps of cancer * Palliative treatment
Conditions HER2-positive Breast Cancer
Phase Not Applicable
Enrollment 2092
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Chemotherapy combined with trastuzumab and patuzumab is the standard neoadjuvant therapy for HER2 positive breast cancer patients. The survival rate of patients with pathological complete response (PCR) after neoadjuvant therapy was significantly better than that of patients with tumor residue, that is, non-PCR. Therefore, studies have confirmed that adjuvant therapy for patients with non-PCR after neoadjuvant chemotherapy can further improve the prognosis and survival of this population. However, the results of previous studies are based on trastuzumab target therapy in neoadjuvant therapy. Therefore, there are different recommendations for the current guidelines of adjuvant therapy after trastuzumab combined pertuzumab target neoadjuvant therapy. Patients with HER2 positive breast cancer who received trastuzumab and patuzumab based neoadjuvant therapy had invasive residual cancer in postoperative pathology. The effect of postoperative adjuvant therapy with trastuzumab and patuzumab or replacement of T-DM1 on survival.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Primary Outcomes

  • invasive disease free survival (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-01-01
Completion: 2031-12-31
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 2092 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shu Wang
Principal Investigators:
  • shu wang, doctor (PRINCIPAL_INVESTIGATOR) - Peking University People's Hospital
Contact Information
Study Contact:
yuan peng, doctor
86+13671287670
13671287670@163.com
yuan peng, Dr
Peking University People's Hospital
Interventions
N/A
Study Locations (1 sites)
Peking University People's Hospital, Beijing, Beijing Municipality 100044 China
Eligibility Criteria
Inclusion Criteria: * 1\) Patients with HER2 positive breast cancer were diagnosed by biopsy in Peking University People's hospital; * 2\) The clinical stages before treatment were T1-T4, N0-N3, M0; * 3\) Received treatment and operation in our hospital, and had hospitalization records; * 4\) Receive at least 4 cycles of trastuzumab and pertuzumab target therapy combined chemotherapy as neoadjuvant therapy * 5\) Postoperative pathology confirmed the presence of residual invasive breast cancer in the breast and/or metastatic tumor lesions in axillary lymph nodes; * 6\) Has signed and agreed to participate in the PKUPH breast disease cohort study. Exclusion Criteria: * 1\) Lack of clinical and pathological data (such as imaging data and pathological data); * 2\) Patients with metastatic breast cancer or bilateral breast cancer; * 3\) Failure to perform radical surgery; * 4\) Receiving other regimens besides the established neoadjuvant regimens.
Conditions Breast Cancer Female, Thyroid Gland
Phase Not Applicable
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer is one of the most common cancers in China. Even though advances in the field of breast cancer therapeutics, chemotherapy remains the mainstay therapeutic modality. The cytotoxic therapies are generally associated with some immediate or otherwise delayed side effects, such as adverse effects on gastrointestinal, hepatic, renal and hematological systems. The effect of chemotherapy on endocrine system, however, is comparatively less envisaged. Several epidemiological studies show a positive association between plasma thyroid hormones levels and breast cancer risk. Thyroid dysfunction is emerging as a variably common endocrine toxicity of several anticancer drugs. Due to the scarcity of data on the functioning of thyroid gland during chemotherapy in a large scale group, the present study was aimed to investigate the incidence of thyroid abnormity in Chinese women with newly diagnosed breast cancer, and also the effects of chemotherapy on thyroid gland functions or structure in these breast cancer patients undergoing at least four cycles of chemotherapy.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Chemotherapy — Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy.

Primary Outcomes

  • Number of participants newly diagnosed with breast cancer (1 week around the indicated detection point)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2017-06-04
Completion: 2027-06
Eligibility
Age: 18 Years – 85 Years
Sex: FEMALE
Volunteers: Not specified
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital of Bengbu Medical University
Principal Investigators:
  • Qiong Wu, M.D.,Ph.D. (PRINCIPAL_INVESTIGATOR) - The First Affiliated Hospital of Bengbu Medical University
Contact Information
Study Contact:
Yan Yang, M.D.,Ph.D.
+86-552-3086178
qiannianhupo@163.com
Yan Yang, M.D., Ph.D.
+86-552-3086178
qiannianhupo@163.com
Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College
Qiong Wu, M.D., Ph.D.
Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College
Interventions
  • Drug: Chemotherapy — Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy.
Study Locations (1 sites)
Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004 China
Eligibility Criteria
Inclusion Criteria: 1. Female patients with histologically or cytologically proven primary breast cancer; 2. Age \>18 years; 3. ECOG Performance Status: 0-2; 4. Life Expectancy: 3 months or more; 5. No previous anti-cancer therapy; 6. Be willing to undergo at least four cycles of anthracycline or taxane-based chemotherapy; 7. Adequate hematological, liver, and kidney functions. Exclusion Criteria: 1. Pregnancy or lactation; 2. History of other malignancy or secondary breast cancer; 3. History of thyroid disease; 4. History of drug addiction or abuse; 5. History of immunodeficiency disease; 6. Treatment with drugs capable of influencing thyroid gland functions within 3 months prior to study entry; 7. Nonmeasurable disease such as un-controlled diabetes, severe cardiovascular and cerebrovascular diseases; 8. Current, recent (within 4 weeks prior to study entry), or planned participation in any other clinical trials; 9. Inability to understand and agree to informed consent.
Conditions Advanced Breast Cancer, Advanced Breast ...
Phase PHASE2
Enrollment 200
Locations 79 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This trial studies a type of advanced breast cancer defined as hormone receptor HR-positive/HER2-negative and classified as non-luminal by gene expression profiling (PAM50). Patients will be treated with trastuzumab deruxtecan (T-DXd) or with physician's choice of CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET). The main purpose of the study is to analyze the efficacy of T-DXd in patients who have HR-positive and HER2-low/ultralow advanced breast cancer classified as non-luminal subtype.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Trastuzumab deruxtecan (T-DXd, DS-8201a) — Patients will receive T-DXd 5.4 mg/kg body weight administered as an intravenous (IV) infusion on Day 1 (D1) of each 21-day cycle. The initial dose will be administered as a 90-minute IV infusion.
  • Drug: CDK4/6i plus ET — Patients will receive physician's choice of CDK4/6 inhibitor (CDK4/6i) including palbociclib, ribociclib, and abemaciclib; physician's choice of endocrine therapy (ET) including fulvestrant, letrozole, anastrozole, and exemestane.

Primary Outcomes

  • Progression-free survival (PFS) (Up to 25 months)
  • Progression-free survival (PFS) (Up to 25 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-06-30
Completion: 2028-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: MedSIR
Contact Information
Study Contact:
MEDSIR
+ 34 932 214 135
contact.trials@medsir.org
Interventions
  • Drug: Trastuzumab deruxtecan (T-DXd, DS-8201a) — Patients will receive T-DXd 5.4 mg/kg body weight administered as an intravenous (IV) infusion on Day 1 (D1) of each 21-day cycle. The initial dose will be administered as a 90-minute IV infusion.
  • Drug: CDK4/6i plus ET — Patients will receive physician's choice of CDK4/6 inhibitor (CDK4/6i) including palbociclib, ribociclib, and abemaciclib; physician's choice of endocrine therapy (ET) including fulvestrant, letrozole, anastrozole, and exemestane.
Study Locations (79 sites)
Medizinische Universität Graz, Graz, Austria
Kepler Universitäts Klinikum, Linz, Austria
Medical University of Vienna, Vienna, Austria
Algemeen Ziekenhuis Klina, Brasschaat, Belgium
Ghent University Hospital, Ghent, Belgium
CHU Helora - Hopital de Mons, Mons, Belgium
Cliniques universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium
Centre Francois Baclesse, Caen, France
CHU Lyon Sud, Lyon, France
Institute Paoli Calmettes, Marseille, France
Eligibility Criteria
Inclusion Criteria: 1. Patients must be capable to understand the purpose of the study and have signed written informed consent form (ICF) prior to beginning specific protocol procedures. 2. Female or male patients ≥ 18 years of age at the time of signing ICF. 3. ECOG performance status of 0-1. 4. Minimum life expectancy of ≥ 12 weeks at screening. 5. Evidence of HER2-low expression (1+ by immunohistochemistry (IHC) or 2+ and negative by an in situ hybridization \[ISH\] test) or HER2-ultralow (IHC 0 with faint membrane staining and in ≤ 10% of tumor cells) breast cancer according to the most recent American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines determined by a MEDSIR's designated central laboratory, using Ventana 4B5 antibody. This assessment has to be done on the most recently available (archived or newly collected) formalin-fixed, paraffin-embedded (FFPE) tumor tissue blocks (≤ 6 weeks or FFPE of a tumor sample obtained after last prior systemic therapy) from core or excisional biopsy from a locally recurrent (breast or locoregional lymph nodes) or metastatic tumor lesion, excluding bone metastases. 6. Non-luminal breast cancer subtype as per central PAM50 analysis determined in the most recently available (archived or newly collected) FFPE tumor tissue blocks (≤ 6 weeks or FFPE of a tumor sample obtained after last prior systemic therapy) from core or excisional biopsy from a locally recurrent (breast or locoregional lymph nodes) or metastatic tumor lesion with the exception of bone metastases. 7. Patients must have HR-positive (estrogen receptor \[ER\] and/or progesterone receptor \[PgR\]-positive defined as ≥ 1% positive stained cells) status according to the most recent ASCO/CAP guidelines locally determined prior to study entry. 8. Unresectable locally recurrent or metastatic breast cancer documented by computerized tomography (CT) scan or magnetic resonance imaging (MRI) that is not amenable to resection with curative intent. 9. Evaluable disease according to RECIST v.1.1. Patients with bone-only disease are not allowed. Patients with bone metastases with soft tissue masses measuring \> 10 mm are eligible. 10. Patients must have endocrine resistance criteria: • disease progression during adjuvant ET or within the first year of completing adjuvant ET; or endocrine sensitivity criteria: • de novo metastatic disease or disease progression ≥ 12 months after completing adjuvant ET with at least one of the following requirements: * Estrogen receptor ≤ 50% positive stained cells; * and/or high histological grade or Ki67 \> 50% on primary tumor; * and/or liver metastases; * and/or known non-luminal subtype as per local PAM50 analysis. 11. No prior treatment with any systemic therapy for advanced disease. 12. Patients treated with a CDK4/6i in the adjuvant setting with a treatment-free interval (TFI) ≥ 12 months following CDK4/6i treatment completion are eligible. 13. Patients have adequate bone marrow, liver, and renal function: * Hematological (without platelet, red blood cell transfusion, and/or granulocyte colony-stimulating factor support within 14 days before first study treatment dose): White blood cell (WBC) count \> 3.0 x 109/L, absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelet count ≥ 100.0 x 109/L, and hemoglobin ≥ 9.0 g/dL (≥ 5.6mmol/L). * Hepatic: Serum albumin ≥ 2.5 g/dL; total bilirubin ≤ 1.5 times upper limit of normal (x ULN) (≤ 3 x ULN in patients with liver metastases or know history of Gilbert's disease); alkaline phosphatase (ALP) ≤ 2.5 x ULN (≤ 5 x ULN in patients with liver/or bone metastases); aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN (≤ 5 x ULN in patients with liver metastases). * Renal: Creatinine clearance ≥ 30 mL/min as determined by Cockcroft Gault (using actual body weight). * Coagulation: International normalized ratio or prothrombin time and either partial thromboplastin or activated partial thromboplastin time ≤ 1.5 × ULN. 14. Resolution of all acute toxic effects of prior anti-cancer therapy to Grade ≤ 1 as determined by the US National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (v.5.0) (except for alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion). 15. Women of childbearing potential who are sexually active with a non-sterilized male partner must have a negative serum pregnancy test within 14 days before study treatment initiation. In addition, they must agree to use one highly effective method of birth control from the time of screening until 7 months after the last dose of T-DXd, or within the time period specified per local prescribing guidelines after the final dose of physician's choice of CDK4/6i plus ET. Female patients must refrain from egg cell donation and breastfeeding during this same period. 16. Male participants who are sexually active with a female partner of childbearing potential must be surgically sterile or using an acceptable method of contraception from the time of screening until 4 months after the last dose of T-DXd, or within the time period specified per local prescribing guidelines after the final dose of physician's choice of CDK4/6i plus ET. Male participants must not donate or bank sperm during this same period. 17. Patients must be accessible for treatment and follow-up. Exclusion Criteria: 1. Current participation in another therapeutic clinical trial, except other translational studies. 2. Treatment with approved or investigational cancer therapy within 3 weeks prior to initiation of study drug. 3. Treatment with chloroquine/hydroxychloroquine within 14 days prior to initiation of study drug. 4. Have previously been treated with T-DXd and/or fulvestrant. Note: patients who experienced relapse after more than 1 year from completion of fulvestrant are eligible. Note I: previous treatment with anti-HER2 therapies in (neo-) adjuvant setting will be allowed for participants who showed conversion from HER2-positive expression in primary breast tumor sample to HER2-low or HER2-ultralow expression (HER2 loss) in relapsed tumor sample. 5. Patients with advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term (including patients with massive uncontrolled effusions \[pleural, pericardial, and/or peritoneal\] and pulmonary lymphangitis). 6. Impairment of gastro-intestinal (GI) function or GI disease that may significantly alter the absorption of CDK4/6i, such as history of GI surgery which may result in intestinal blind loops and patients with clinically significant gastroparesis, short bowel syndrome, unresolved nausea, vomiting, active inflammatory bowel disease, or diarrhea of CTCAE Grade \> 1. 7. Known central nervous system (CNS) involvement (brain metastases and/or leptomeningeal carcinomatosis). Subjects with clinically inactive brain metastases may be included in the study. Subjects with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. 8. Have a concurrent malignancy or malignancy within 5 years of study enrollment with the exception of carcinoma in situ of the cervix and basal cell carcinoma or squamous cell carcinoma of the skin that has been previously treated with curative intent. For other cancers considered to have a low risk of recurrence, discussion with the Sponsor's Medical Monitor is required. 9. Known allergy or hypersensitivity reaction to any of the investigational medicinal products (IMPs) or their inactive ingredients. 10. Palliative radiotherapy with a limited field of radiation within 2 weeks or with wide field of radiation or to more than 30% of the bone marrow within 4 weeks prior to start of study treatment. 11.
Conditions TNBC, TNBC - Triple-Negative Breast Canc...
Phase PHASE2
Enrollment 34
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This is a single arm phase II trial combination of ivonescimab and carbo-docetaxel every 3 weeks for 6 cycles in patients with early-stage triple negative breast cancer. The trial is designed to test the safety and efficacy of adding ivonescimab in patients with early TNBC undergoing neoadjuvant chemotherapy with carboplatin and docetaxel. Patients will receive ivonescimab 20 mg/kg IV on Day 1 of each cycle, and carboplatin AUC6 and docetaxel 75 mg/m2 on Day 1 of each cycle for 6 cycles. Cycles will be 21 days for a total of 6 cycles. Curative intent surgery will be performed within 6 weeks (maximum 12 weeks) time frame upon completion of last dose of chemoimmunotherapy. The surgical pathology information will be used for assessment of pathological response, which serve as the primary endpoint of this study. Patients will undergo assessment at baseline, C1D1 of each cycle and end of treatment visit for collection of treatment-emergent adverse events, evaluated by CTCAE v5.0. Patient reported outcomes will be collected at cycles 1, 4, and 6, and at EOT. All study patients will be followed for at least 5 years for EFS and OS follow up. Research biopsies, peripheral blood and stool samples will be collected at the following time points: baseline, C4D1 (+/-14 days), and surgery (+/-14 days). Baseline and EOT breast MRI will be performed as standard of care for assessment of clinical response. Mid treatment breast ultrasound (C4D1 +/-14 days) will be repeated as standard of care to assess clinical response to treatment. Mid-treatment C4D1 tumor biopsy may be omitted if the primary tumor is no longer visible or the tumor deemed too small for biopsy by radiologist.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Ivonescimab — Drug: Ivonescimab Dose: 20 mg/kg Route: IV infusion over 60 minutes Frequency: Q3W Duration: 6 cycles (Each cycle is 21 days)
  • Drug: Carboplatin — Drug: Carboplatin Dose: AUC6 Route: IV infusion Frequency: Q3W Duration: 6 cycles (Each cycle is 21 days)
  • Drug: Docetaxel — Drug: Docetaxel Dose: 75 mg/m\^2 Route: IV infusion over 60 minutes Frequency: Q3W Duration: 6 cycles (Each cycle is 21 days)

Primary Outcomes

  • Pathological complete response (pCR) rate (6 months (From cycle 1 day 1 till surgery))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-07-25
Completion: 2032-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 34 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cedars-Sinai Medical Center
Collaborators: Summit Therapeutics
Principal Investigators:
  • Yuan Yuan, MD (PRINCIPAL_INVESTIGATOR) - Cedars-Sinai Medical Center
Contact Information
Study Contact:
Clinical Trial Navigator
310-423-5842
GroupCancerTrialInformation@cshs.org
Yuan Yuan, MD
yuan.yuan@csmc.edu
Clinical Trial Recruitment Navigator
310-423-5842
GroupCancerTrialInformation@cshs.org
Cedars-Sinai Medical Center
Interventions
  • Drug: Ivonescimab — Drug: Ivonescimab Dose: 20 mg/kg Route: IV infusion over 60 minutes Frequency: Q3W Duration: 6 cycles (Each cycle is 21 days)
  • Drug: Carboplatin — Drug: Carboplatin Dose: AUC6 Route: IV infusion Frequency: Q3W Duration: 6 cycles (Each cycle is 21 days)
  • Drug: Docetaxel — Drug: Docetaxel Dose: 75 mg/m\^2 Route: IV infusion over 60 minutes Frequency: Q3W Duration: 6 cycles (Each cycle is 21 days)
Study Locations (4 sites)
Cedars-Sinai Medical Center, Los Angeles, California 90048 United States
Cedars-Sinai Medical Center Beverly Hills, Los Angeles, California 90211 United States
Huntington Cancer Center, an Affiliate of CS Cancer, Pasadena, California 91105 United States
Hunt Cancer Institute, an Affiliate of CS Cancer, Torrance, California 90505 United States
Eligibility Criteria
Inclusion Criteria * Age ≥ 18 years of age * ECOG ≤ 1 * High-risk early stage triple negative breast cancer (TNBC), defined by ER≤10%, PR≤10% and HER2 negative (by IHC or FISH), per ASCO/CAP guidelines * Clinically ≥T1cN0, or any T, N1-2 * Plan to receive neoadjuvant chemotherapy and immune checkpoint inhibitor before surgery as standard-of-care treatment * Adequate organ function as defined in the following. Specimens must be collected within 14 days prior to the start of study treatment. * ANC ≥ 1,500/mm3 * Platelets ≥ 100,000/mm3 * Hemoglobin ≥ 9.0 g/dL. * Total serum bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ULN for participants with total bilirubin levels \>1.5 x ULN * AST \< 3 x ULN * ALT \< 3 x ULN * Creatinine clearance ≥ 30 mL/min * INR or PT, aPTT \< 1.5 x ULN * Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test within 14 days of start of study treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Note: If egg harvesting was completed prior to enrollment, the pregnancy test may be falsely positive and the PI will assess and determine eligibility for these cases. * Female participants: A female participant is eligible to participate if she is not pregnant (see Appendix B), not breastfeeding, and at least one of the following conditions applies: \-- Not a woman of childbearing potential (WOCBP) as defined in Appendix B OR Females of child-bearing potential must be willing to use effective contraception during study and for 120 days after the last dose. * Male participants: A male participant must agree to use a contraception as detailed in Appendix B of this protocol during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period. * Written informed consent obtained from subject and ability for subject to comply with the requirements of the study. Exclusion Criteria * Evidence of metastatic disease. * Is currently participating in or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment. * History of bleeding tendencies or coagulopathy and/or clinically significant bleeding symptoms or risk within 4 weeks prior to start of study treatment, including but not limited to: * Hemoptysis (defined as coughing up ≥ 0.5 teaspoon of fresh blood or small blood clots) Note: transient hemoptysis associated with diagnostic bronchoscopy is allowed. * Nasal bleeding/epistaxis (bloody nasal discharge is allowed) * Current use of prophylactic or full-dose anticoagulants or anti-platelet agents for therapeutic purposes that is not stable, in the opinion of the treating investigator, prior to start of study treatment is not allowed. The use of full-dose anticoagulants is permitted as long as the INR or activated partial thromboplastin time (aPTT) is within therapeutic limits according to the medical standard of the enrolling institution. * Poorly controlled hypertension with repeated systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg after oral antihypertensive therapy * Women who are or are planning to become pregnant or breastfeed * Known allergy to any of the components within the study agents and/or their excipients * Medical history and concurrent diseases * Autoimmune diseases * Any prior malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for at least three years * History of (non-infectious) pneumonitis that required steroids or has current pneumonitis * Active infection requiring systemic therapy * Known history of Human Immunodeficiency Virus (HIV) infection * Known history of active Hepatitis B (defined as Hepatitis B surface antigen \[HBsAg\] reactive) or known active Hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority * Known history of active TB (Mycobacterium tuberculosis) * History of unstable angina, myocardial infarction, congestive heart failure (New York Heart Association \[NYHA\] classification ≥ grade 2) or unstable vascular disease (eg, aortic aneurysm at risk of rupture, Moyamoya disease) that required hospitalization within 12 months prior to randomization, or other cardiac impairment that may affect the safety evaluation of the study drug (eg, poorly controlled arrhythmias, myocardial ischemia) * Prolongation of QTc interval \>480 msec * Prior allogeneic bone marrow transplantation or prior solid organ transplantation * History of esophageal gastric varices, severe ulcers, wounds that do not heal, abdominal fistula, intra-abdominal abscesses, or acute gastrointestinal bleeding within 6 months prior to start of study treatment * History of any grade arterial thromboembolic event, Grade 3 and above venous thromboembolic event, as specified in National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 5.0, transient ischemic attack, cerebrovascular accident, hypertensive crisis, or hypertensive encephalopathy within 12 months prior to start of study treatment * Acute exacerbation of chronic obstructive pulmonary disease within 4 weeks before start of study treatment * History of perforation of the gastrointestinal tract and/or fistula, history of gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive bowel resection (partial colectomy or extensive small bowel resection) within 6 months prior to start of study treatment * Prohibited Treatments and/or Therapies * Other non-protocol specified anti-cancer therapy: systemic radiotherapy, immunotherapy, biologic, or hormonal therapy. tretinoin therapy, nitrosourea, mitomycin C, small molecule tyrosine kinase inhibitor therapy \--- Concomitant use of hormones for non-tumor-related conditions (e.g., insulin and hormone replacement therapy for diabetes mellitus) is acceptable * Any live vaccine within 30 days prior to the first dose of study drug and up to 120 days after the last dose. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed * Prior systemic therapy or radiation therapy with curative intent for the current breast cancer * A previous definitive ipsilateral breast surgery for the current breast cancer * Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. CTLA-4, OX-40, CD137). * Immunosuppressive drugs, including, but not limited to, prednisone or equivalent, methotrexate, azathioprine, and TNF-α antagonists at doses exceeding 10 mg per day. The following exceptions are allowed: * The use of immunosuppressive drugs for the treatment of study drug-associated AEs or the use of immunosuppressive drugs in subjects with contrast allergy is acceptable. * The use of inhaled, topical, and intranasal glucocorticoids is permitted. * Corticosteroids are allowed as a prophylactic drug for hypersensitivity reactions (eg, before CT or MRI). * Corticosteroids are allowed as antiphylactic and therapeutic agents for chemotherapy-induced vomiting. * Short-term use of glucocorticoids for underlying or intercur
Conditions Breast Cancer Survivors
Phase NA
Enrollment 72
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

There are more than 3.8 million breast cancer survivors in the United States and cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect of a novel exercise intervention on cardiovascular rehabilitation in breast cancer survivors.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Exercise training — This is a single site center-based supervised exercise intervention.

Primary Outcomes

  • Change in brachial FMD (Baseline, Following 12 weeks of supervised exercise training)
  • Change in global longitudinal strain (Baseline, Following 12 weeks of supervised exercise training)
  • % completed vs. planned exercise frequency (Throughout the 12 weeks of supervised exercise training)
  • % completed vs. planned exercise duration (Throughout the 12 weeks of supervised exercise training)
  • % completed vs. planned exercise intensity (Throughout the 12 weeks of supervised exercise training)
  • Number of participants who experience adverse event as defined by most recent CTCAE (Throughout the 12 weeks of supervised exercise training)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-26
Completion: 2027-12
Eligibility
Age: 40 Years – 80 Years
Sex: FEMALE
Volunteers: false
Enrollment: 72 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Florida
Principal Investigators:
  • Demetra Christou, PhD (PRINCIPAL_INVESTIGATOR) - University of Florida
Contact Information
Study Contact:
Demetra Christou, PhD
352-294-1746
ddchristou@ufl.edu
Demetra Christou, PhD
352-294-1746
ddchristou@ufl.edu
Integrative Cardiovasculal Physiology Laboratory, University of Florida
Interventions
  • Behavioral: Exercise training — This is a single site center-based supervised exercise intervention.
Study Locations (1 sites)
Integrative Cardiovasculal Physiology Laboratory, University of Florida, Gainesville, Florida 32611 United States
Eligibility Criteria
Inclusion Criteria: * diagnosis of primary invasive non-metastatic breast cancer, stages I-III * female based on biological sex * 40 to 80 years of age * completed breast cancer treatment 6 to 24 months prior to study enrollment. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy and bisphosphonates are allowed within 6 months prior to study enrollment and during study participation * absence of contraindications to exercise or study participation * study clinician approval Exclusion Criteria: * do not meet inclusion criteria * receiving or scheduled to receive treatment for breast cancer (i.e., chemotherapy, surgery, or radiation) during study participation is not allowed. Adjuvant endocrine therapy, CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy and bisphosphonates are allowed during study participation * lymphedema stage ≥ 2 prior to study enrolment * any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent) * current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss) * consistent participation in ≥150 min/week of moderate-intensity rowing exercise training in previous 6 months